| Literature DB >> 25926836 |
Ilaria Panzeri1, Grazisa Rossetti1, Sergio Abrignani1, Massimiliano Pagani2.
Abstract
Upon recognition of a foreign antigen, CD4(+) naïve T lymphocytes proliferate and differentiate into subsets with distinct functions. This process is fundamental for the effective immune system function, as CD4(+) T cells orchestrate both the innate and adaptive immune response. Traditionally, this differentiation event has been regarded as the acquisition of an irreversible cell fate so that memory and effector CD4(+) T subsets were considered terminally differentiated cells or lineages. Consequently, these lineages are conventionally defined thanks to their prototypical set of cytokines and transcription factors. However, recent findings suggest that CD4(+) T lymphocytes possess a remarkable phenotypic plasticity, as they can often re-direct their functional program depending on the milieu they encounter. Therefore, new questions are now compelling such as which are the molecular determinants underlying plasticity and stability and how the balance between these two opposite forces drives the cell fate. As already mentioned, in some cases, the mere expression of cytokines and master regulators could not fully explain lymphocytes plasticity. We should consider other layers of regulation, including epigenetic factors such as the modulation of chromatin state or the transcription of non-coding RNAs, whose high cell-specificity give a hint on their involvement in cell fate determination. In this review, we will focus on the recent advances in understanding CD4(+) T lymphocytes subsets specification from an epigenetic point of view. In particular, we will emphasize the emerging importance of non-coding RNAs as key players in these differentiation events. We will also present here new data from our laboratory highlighting the contribution of long non-coding RNAs in driving human CD4(+) T lymphocytes differentiation.Entities:
Keywords: epigenetic regulation; long non-coding RNAs; lymphocyte differentiation
Year: 2015 PMID: 25926836 PMCID: PMC4397839 DOI: 10.3389/fimmu.2015.00175
Source DB: PubMed Journal: Front Immunol ISSN: 1664-3224 Impact factor: 7.561
Major classes of short and long regulatory non-coding RNAs.
| ncRNA | Length (nt) | Function | |
|---|---|---|---|
| miRNAs | Micro RNAs | 21–23 | In animals, associate with the miRNA-induced silencing complex (RISC) and silence the expression of target genes mostly post-transcriptionally ( |
| snoRNAs | Small nucleolar RNAs | 60–300 | Help the chemical modification of mRNAs, thereby influencing stability, folding, and protein-interaction properties ( |
| snRNAs | Small nuclear RNAs | 150 | Assist splicing of introns from primary genomic transcripts ( |
| piRNAs | Piwi-interacting RNAs | 25–33 | Associate with the highly conserved Piwi family of argonaute proteins and are essential for retrotransposon silencing in germline, epigenetic modifications, DNA rearrangements, mRNA turnover, and translational control also in soma ( |
| PASRs | Promoter-associated short RNAs | 22–200 | Enriched at the 5′end of genes, within 0.5 kb of TSS. Can be transcribed both sense and antisense. Their function and biogenesis is not fully understood ( |
| TASRs | Termini-associated short RNAs | 22–200 | Can be transcribed both sense and antisense near termination sites of protein-coding genes. Their function and biogenesis is not fully understood ( |
| siRNAs | Short interfering RNAs | 21–23 | Processed from a plethora of genomic sources, both foreign (viruses) and endogenous (repetitive sequences). Canonically induce the degradation of perfectly complementary target RNAs ( |
| tiRNAs | Transcription initiation RNAs | 15–30 | Enriched immediately downstream transcriptional start sites (TSSs) of highly expressed genes. Their function and biogenesis is not fully understood ( |
| NATs | Natural antisense transcripts | >200 | Transcribed from the same locus but opposite strand of the overlapping protein-coding sequence. Involved in gene expression regulation, RNA editing, stability, and translation ( |
| PALRs | Promoter-associated long RNAs | 200–1000 | Enriched at promoters, found to regulate gene expression ( |
| PROMPTs | Promoter upstream transcripts | 200–600 | Enriched at TATA-less, CpG-rich promoters with broad TSSs. Affect promoter methylation and regulate transcription ( |
| T-UCRs | Transcribed ultraconserved regions | >200 | Perfectly conserved between human, rat, and mouse. Frequently located at fragile sites and at genomic regions involved in cancer ( |
| Intronic RNAs | >200 | Transcribed from introns of overlapping protein-coding sequences. Involved in the control of gene expression, alternative splicing, and source for generation of shorter regulatory RNAs ( | |
| eRNAs | Enhancer-derived RNAs | >200 | Function still not completely understood. May functionally contribute to the enhancer function ( |
| LincRNAs | Long intervening (intergenic) RNAs | >200 | Gene expression regulation, regulation of cellular processes ( |
| uaRNAs | 3′UTR-derived RNAs | <1000 | Derive within 3′untranslated region (3′UTR) sequences. Function still not clearly understood ( |
| circRNA | Circular RNA | 100 to >4000 | Diverse, from templates for viral replication to transcriptional regulators ( |
Examples of lincRNAs with key roles in various cellular contexts.
| LncRNA | Cellular context | Function |
|---|---|---|
| H19 | HSC, placenta | Maternally expressed imprinted gene important for inhibiting placental |
| GAS5 | T lymphocytes, cancers | Plays an essential role in normal |
| Linc-MD1 | Muscles | Governs the timing of muscle |
| Xist | Somatic cells | Expressed by the future inactive X chromosome, triggers gene silencing |
| KCNQ1OT1 | Most tissues | Paternally expressed antisense transcript to an interior portion of |
Figure 1Examples of the main functions associated to lincRNAs. (1–5) LincRNAs described in the immune system. (1) Modulation of cell growth and apoptosis mediated by GAS5 that acts inhibiting glucocorticoid receptors binding to their DNA responsive elements; (2) Jα recombination guided by the PARL TEA; (3) Tmevpg1 recruits WDR5 to induce IFNγ expression; (4) Nron modulates the import–export of NFAT to the nucleus; (5) IFNα1-AS acts as a competing endogenous RNA, releasing IFNα from micro-RNA inhibition. In light red other mechanisms are described for lincRNAs outside the immune system.
Studies on lncRNAs in the adaptive immune system.
| Sample | LncRNAs | Function |
|---|---|---|
| Granulocytes, monocytes, NK, B, naïve CD8+ and CD4+, memory human T cells; | 240 lncRNAs associated with autoimmune disease (AID) loci (RNA-seq) | Analysis of the expression profile of the AID-associated lncRNAs ( |
| CD4−CD8−, CD4+CD8+, CD4+CD8−, activated CD4+ mouse T cells | 31423 lncRNAs (lncRNA microarray) | Expression analysis and prediction of function ( |
| 17 T-cell leukemia cell lines | Thy-ncR1 (expression profiling of 10 thymus-specific ncRNA) | Enriched in human immature cells; acts as a cytoplasmic riboregulator that reduces the level of MFAP4 mRNA ( |
| Naïve, memory, activated, non-activated mouse CD8+ T cells | Over 1000 mouse and human lncRNAs (microarray) | Expression and conservation analysis ( |
| CD4−CD8−, CD4+CD8+, CD4+, CD8+ mouse thymic T cells, and thymus-derived Treg cells. | 1524 lincRNA genes (RNA-seq); LincR-Ccr2-5′AS | Expression analysis and ChIP-seq data analysis to identify lincRNA genes and possible regulators. LincR-Ccr2-5′AS is TH2-specific and it reduces the expression of |
| Infected Namalwa B lymphocytes | IFNA1-AS | Cytoplasmic post-transcriptional stabilization of IFN-α1 RNA masking a miRNA-binding site ( |
| Jurkat cells, primary lymphomas, lymphoma cell lines, CD19+ B cells | Saf/FAS-AS1 | Regulates the alternative splicing of Fas which is impaired in non-Hodgkin’s lymphomas associated with poor prognosis ( |
| Activated human CD4+ T cells | Proto-oncogene, induced upon activation, sensitive to immunosuppressive drugs ( | |
| Jurkat cells | NRON (shRNA knock-down screening) | Regulates NFAT subcellular localization as part of an RNA–protein complex ( |
| CEM-C7 CKM1, jurkat JKM1, human primary lymphocytes | GAS5 | Necessary and sufficient for growth arrest. Acts competing from GREs ( |
| Human CD4+, CD8+ cells, PBMC | Unknown, it shows a similar expression pattern to | |
| Thymocytes | TEA | Instruct the activity of Jα promoters and recombination ( |
| Human TH1 cells | NeST/Tmevpg1/IFNG-AS1 | Dependent on STAT4, T-bet, and NFκB. Contributes to |
| Human primary CD4+ and CD8+ T cells, primary and polarized (from CD4+ and CD8+ T) CD4+ CM, TH1, TH2, TH17, and Treg cells; neutrophils, basophils, CD8+ CM, B cells | Specifically expressed in TH 2 cells ( |
Figure 2Mechanism of action proposed for linc-MAF-4.